- Home
- KINS vs FHTX Comparison
KINS vs FHTX Comparison
Compare KINS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- FHTX
- Stock Information
- Founded
- KINS 1886
- FHTX 2015
- Country
- KINS United States
- FHTX United States
- Employees
- KINS N/A
- FHTX N/A
- Industry
- KINS Property-Casualty Insurers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- KINS Finance
- FHTX Health Care
- Exchange
- KINS Nasdaq
- FHTX Nasdaq
- Market Cap
- KINS 197.1M
- FHTX 227.5M
- IPO Year
- KINS N/A
- FHTX 2020
- Fundamental
- Price
- KINS $16.99
- FHTX $3.52
- Analyst Decision
- KINS Strong Buy
- FHTX Strong Buy
- Analyst Count
- KINS 1
- FHTX 6
- Target Price
- KINS $6.50
- FHTX $13.17
- AVG Volume (30 Days)
- KINS 301.5K
- FHTX 99.9K
- Earning Date
- KINS 03-13-2025
- FHTX 03-06-2025
- Dividend Yield
- KINS N/A
- FHTX N/A
- EPS Growth
- KINS N/A
- FHTX N/A
- EPS
- KINS 1.48
- FHTX N/A
- Revenue
- KINS $155,142,103.00
- FHTX $22,602,000.00
- Revenue This Year
- KINS $39.05
- FHTX $44.46
- Revenue Next Year
- KINS $3.26
- FHTX $24.12
- P/E Ratio
- KINS $11.48
- FHTX N/A
- Revenue Growth
- KINS 7.59
- FHTX N/A
- 52 Week Low
- KINS $3.93
- FHTX $3.52
- 52 Week High
- KINS $19.18
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- KINS 56.09
- FHTX 31.22
- Support Level
- KINS $16.20
- FHTX $3.75
- Resistance Level
- KINS $17.77
- FHTX $4.73
- Average True Range (ATR)
- KINS 1.00
- FHTX 0.36
- MACD
- KINS 0.28
- FHTX -0.07
- Stochastic Oscillator
- KINS 81.94
- FHTX 0.36
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.